Session » Vasculitis Poster II: ANCA-Associated Vasculitis

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1753

“Recurrent Venous Thromboembolic Events in Granulomatosis with Polyangiitis Patients”

9:00AM-11:00AM: Abstract Number: 1776

Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan

9:00AM-11:00AM: Abstract Number: 1770

ANCA-Associated Vasculitis (AAV) in Younger Vs Older Patients: Comparison of Clinical, Serologic and Outcome Differences and Their Implications for Management

9:00AM-11:00AM: Abstract Number: 1751

Association of a TNFSF4 Upstream Region Single Nucleotide Polymorphism with Susceptibility to Proteinase 3-ANCA Positive Vasculitis in a Japanese Population

9:00AM-11:00AM: Abstract Number: 1762

Association of ETS1 Polymorphism in 3’ Untranslated Region with Susceptibility to Granulomatosis with Polyangiitis and Proteinase 3-ANCA Positive Vasculitis in a Japanese Population

9:00AM-11:00AM: Abstract Number: 1754

Childhood- Vs. Adult-Onset ANCA-Associated Vasculitides: A Nested, Matched Case–Control Study from the French Vasculitis Study Group Registry

9:00AM-11:00AM: Abstract Number: 1768

Cocaine and ANCA Associated Vasculitis-like Syndromes – a Case Series

9:00AM-11:00AM: Abstract Number: 1761

Differential Characteristics of MPO-ANCA Positive and Negative Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1759

Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study

9:00AM-11:00AM: Abstract Number: 1777

Incidence and Prevalence of Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Health Management Organization: A 15-Year Study

9:00AM-11:00AM: Abstract Number: 1769

Incidence, Predictors, and Outcome of Diffuse Alveolar Hemorrhage in Patients with MPO-ANCA Positive Microscopic Polyangiitis: A Multi-Center Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1766

Increased Renal Damage in Hypocomplementemic Patients with ANCA- Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1756

Interstitial Lung Disease in ANCA Associated Vasculitis: A Distinct or an Incomplete Subset in ANCA Vasculitis Patients?

9:00AM-11:00AM: Abstract Number: 1782

Mycophenolic Acid Decreases IL-10 and IL-6 Production By B Cells of Granulomatosis with Polyangiitis Patients and Healthy Controls in Vitro

9:00AM-11:00AM: Abstract Number: 1773

New Use for an Old Drug: Hydroxychloroquine for the Treatment of ANCA Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1772

Non-Protocolized Re-Biopsy in Patients with ANCA-Associated Glomerulonephritis: ¿Is It Necessary?

9:00AM-11:00AM: Abstract Number: 1779

Off-Label Use of Biological Therapies in Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)

9:00AM-11:00AM: Abstract Number: 1752

Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1781

Pituitary Disease and Granulomatosis with Polyangiitis: A Collaborative Canadian Case Series and Review of the Literature

9:00AM-11:00AM: Abstract Number: 1771

Prevalence and Prognostic Relevance of Cardiovascular Involvement in ANCA-Associated Vasculitis: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1780

Prognostic Factors in Patients with Granulomatosis with Polyangiitis Requiring Hospitalization- a 10 Year Nationwide Analysis

9:00AM-11:00AM: Abstract Number: 1778

Prophylactic Treatment and Incidence of Pneumocystis Jirovecci Pneumonia in Japanese Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1760

Pulmonary Manifestations in Microscopic Polyangiitis and Granulomatosis with Polyangiitis: A Multicenter Cohort Analysis

9:00AM-11:00AM: Abstract Number: 1750

Risk of Cardiovascular and Thrombotic Disease Among Patients with Incident ANCA-Associated Vasculitis: A 20 Year Population Based Cohort Study

9:00AM-11:00AM: Abstract Number: 1758

Risk of Serious Infection in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of 126 Wegent Trial Patients

9:00AM-11:00AM: Abstract Number: 1757

Rituximab for Induction and Maintenance Therapy of Granulomatosis with Polyangiitis: A Single-Center Cohort Study on 114 Patients

9:00AM-11:00AM: Abstract Number: 1755

Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1774

Serum Periostin As a Biomarker in Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1764

Small RNA Sequencing Shows Differential Plasma Microrna Expression in Patients with ANCA-Associated Vasculitis: A Pilot Study

9:00AM-11:00AM: Abstract Number: 1767

The Effect on Health-Related Quality of Life of Treatment for Remission Maintenance in ANCA-Associated Vasculitis Beyond 18 Months

9:00AM-11:00AM: Abstract Number: 1749

The Epidemiology of ANCA Associated Vasculitis in the U.S.: A 20 Year Population Based Study

9:00AM-11:00AM: Abstract Number: 1775

The Utility of the ACR/EULAR 2017 Provisional Classification Criteria for Granulomatosis with Polyangiitis in Korean Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1783

The Value of a Combination of Serum Proteins to Identify Response to Induction Therapy Among Patients with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1763

Time to Diagnosis of ANCA-Associated Vasculitides : Data from French Vasculitis Study Group Registry

9:00AM-11:00AM: Abstract Number: 1765

Validation of the ACR EULAR Provisional 2017 Classification Criteria of Granulomatosis with Polyangiitis (GPA) Amongst Patients with ANCA Associated Vasculitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].